je.st
news
Tag: similar
'Very Similar, If Not Identical': U.S. Govt's Lead Prosecutor in Big...
2015-11-13 06:24:48| Oil & Gas - Topix.net
" 'Very Similar, If Not Identical': U.S. Govt's Lead Prosecutor in Big Tobacco Case on the Emerging Case Against ExxonMobil: 'BradCast' 11/12/2015 " 'GNR' Special Coverage: 2016 Republican and Democratic Presidential candidates talk climate, energy, and the path forward in GOP Debate and Dem Forum --- or not... Screenshots suggest disappearing 'Yes' votes; OH SoS offers us an explanation.
Tags: big
similar
lead
prosecutor
Argonne analysis shows greenhouse gas emissions similar for shale, conventional oil
2015-10-16 11:55:32| Green Car Congress
Tags: similar
shows
analysis
gas
US Hog Numbers Remain Same; Weights to Track Similar
2015-09-30 02:00:00| ThePigSite - Industry News
US - The USDA’s quarterly Hogs and Pigs report contained no surprises for the trade and Lean Hogs futures reflect that fact by being quiet at mid-day on Monday. The key national data from the report appear in Figure 1, writes Steve Meyer in the National Hog Farmer.
Tags: similar
track
numbers
remain
Hog numbers remain same; weights to track similar
2015-09-28 21:50:00| National Hog Farmer
The USDAs quarterly Hogs and Pigs report contained no surprises for the trade and Lean Hogs futures reflect that fact by being quiet at mid-day on Monday. read more
Tags: similar
track
numbers
remain
Mercks Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy
2015-09-16 16:16:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that omarigliptin, Mercks investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, achieved its primary efficacy endpoint in a Phase 3 study. Omarigliptin was found to be non-inferior to Mercks once-daily DPP-4 inhibitor, JANUVIA (sitagliptin), at reducing patients A1C* levels from baseline, with similar A1C reductions achieved in both groups. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Michael Close, 310-617-1067Kristen Drake, 917-647-6223orInvestorsJustin Holko, 908-740-1879Teri Loxam, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: on
type
similar
controlled
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] next »